Displaying drugs 8201 - 8225 of 8341 in total
Epothilone D
Investigational
Annamycin
Investigational
FT516
FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). This compound expresses a high-affinity 158V, CD16 (hnCD16) Fc receptor that has an enhanced binding ability to tumor-targeting antibodies, and is resistant to downregulation. FT516 is currently being tested against acute...
Investigational
Fx-1006A
Fx-1006A is a small molecule compound with the potential to treat genetic disorders, such as familial amyloid cardiomyopathy (FAC) and familial amyloid polyneuropathy (FAP).
Investigational
Refametinib
Investigational
Dociparstat sodium
Investigational
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
Abafungin
Investigational
ENMD-1198
Investigational
Onercept
Investigational
AEOL-10150
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
SNS-032
Investigational
Zenarestat
Experimental
Inecalcitol
Investigational
AP1081
A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.
Investigational
Bardoxolone methyl
Investigational
RG-7795
Investigational
Vitespen
Investigational
Interferon Gamma
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Investigational
R-348
Investigational
REV131
rEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Investigational
Axatilimab
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Investigational
PRX-07034
Investigational
Alicaforsen
Investigational
Displaying drugs 8201 - 8225 of 8341 in total